SCHEMBL3210491

SCHEMBL3210491

CN(C)CCNC(=O)c1cccnc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.62
KMT2A Q03164 7/20 0.62
MEN1 O00255 5/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
RAB9A P51151 3/20 0.61
NPC1 O15118 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
EPHX2 P34913 3/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
MAPT P10636 1/20 0.57
ALDH1A1 P00352 1/20 0.57
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.55
USP2 O75604 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
CHRM2 P08172 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29811176 1.00 THRB (0.62) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL5555283 0.91 RAB9A (0.64) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL6525952 0.86 KMT2A (0.59) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL25328235 0.85 THRB (0.77) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL6553954 0.85 KMT2A (0.59) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL6524042 0.85 KMT2A (0.55) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL9274479 0.84 THRB (0.66) THRBKMT2AMEN1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL8010729 0.84 LMNA (0.58) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL16181747 0.83 THRB (0.68) THRBKMT2AMEN1CYP1A2CYP3A4
SCHEMBL2497123 0.83 THRB (0.68) THRBKMT2AMEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2603500-B1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN LA ROCHE (CH) 2014-11-19 EP claimed
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US claimed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 THRB 3449/4885KMT2A 912/4885MEN1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.